[go: up one dir, main page]

MX2009013937A - Nuevo uso de compuestos quimicos farmacologicamente activos conocidos. - Google Patents

Nuevo uso de compuestos quimicos farmacologicamente activos conocidos.

Info

Publication number
MX2009013937A
MX2009013937A MX2009013937A MX2009013937A MX2009013937A MX 2009013937 A MX2009013937 A MX 2009013937A MX 2009013937 A MX2009013937 A MX 2009013937A MX 2009013937 A MX2009013937 A MX 2009013937A MX 2009013937 A MX2009013937 A MX 2009013937A
Authority
MX
Mexico
Prior art keywords
hypertension
new use
chemical compounds
pharmacologically active
arterial
Prior art date
Application number
MX2009013937A
Other languages
English (en)
Inventor
Stefan G Pierzynowski
Original Assignee
Entress Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entress Ab filed Critical Entress Ab
Publication of MX2009013937A publication Critical patent/MX2009013937A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invenci?n se relaciona con el nuevo uso de alfa-cetoglutarato, amidas y sales y mezclas de los mismos para la fabricaci?n de una preparaci?n farmac?utica o complemento para alimento o forraje para el mejoramiento terap?utico in vivo de la elasticidad de vasos sangu?neos, en particular, la elasticidad arterial en un sujeto en necesidad del mismo. El mejoramiento de la elasticidad de los vasos sangu?neos puede utilizarse para el tratamiento y/o profilaxis de la hipertensi?n, hipertensi?n arterial pulmonar, enfermedad cardiovascular, enfermedad vascular retiniana, insuficiencia cardiaca, arterosclerosis, hipertrofia ventricular, accidente cerebrovascular, aneurisma arterial, insuficiencia renal, nefrosclerosis y enfermedades relacionadas con la hipertensi?n.
MX2009013937A 2007-07-02 2008-06-27 Nuevo uso de compuestos quimicos farmacologicamente activos conocidos. MX2009013937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0701602 2007-07-02
PCT/SE2008/050797 WO2009005464A1 (en) 2007-07-02 2008-06-27 New use of known pharmacologically active chemical compounds

Publications (1)

Publication Number Publication Date
MX2009013937A true MX2009013937A (es) 2010-04-30

Family

ID=40226336

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013937A MX2009013937A (es) 2007-07-02 2008-06-27 Nuevo uso de compuestos quimicos farmacologicamente activos conocidos.

Country Status (11)

Country Link
US (1) US20110039935A1 (es)
EP (1) EP2173336B1 (es)
JP (1) JP5735274B2 (es)
KR (1) KR20100039874A (es)
CN (1) CN101730532B (es)
AU (1) AU2008271307B2 (es)
BR (1) BRPI0814184A2 (es)
CA (1) CA2691746C (es)
EA (1) EA018554B1 (es)
MX (1) MX2009013937A (es)
WO (1) WO2009005464A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015123229A1 (en) 2014-02-12 2015-08-20 The Regents Of The University Of California Compositions and methods for treating aging and age-related diseases and symptoms
CN104488333B (zh) 2014-03-20 2019-06-11 华为终端有限公司 发送信号的方法、用户设备和基站
SG10202107237SA (en) * 2017-04-25 2021-08-30 Buck Inst Res Aging Formulations for extending lifespan and healthspan
JP7499259B2 (ja) 2018-09-25 2024-06-13 ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー αケトグルタル酸カルシウムを製造するためのプロセス
EP3980000A4 (en) * 2019-06-10 2023-06-21 Buck Institute for Research on Aging METHODS AND COMPOSITIONS FOR ALTERING THE SENSCENCE OF ASSOCIATED SECRETORY PHENOTYPES
JP2023533452A (ja) * 2020-06-23 2023-08-03 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 動脈瘤を処置するための求電子化合物および求電子プロドラッグ
CN117530940A (zh) * 2023-10-11 2024-02-09 四川大学华西第二医院 α-酮戊二酸在制备促髓鞘修复、改善神经炎症的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402027D0 (sv) * 1994-06-10 1994-06-10 Pharmacia Ab Energy substrates
JP2000093096A (ja) * 1998-09-21 2000-04-04 Snow Brand Milk Prod Co Ltd ゼリー状食品
DE19929993C2 (de) * 1999-06-30 2001-07-05 Sueddeutsche Kalkstickstoff Kreatin-alpha-ketoglutarate, Verfahren zu ihrer Herstellung und ihre Verwendung
CN1203168C (zh) * 2001-08-17 2005-05-25 杨志东 一种制备食疗保健醋的方法及用该方法生产的食疗保健醋
US20040220265A1 (en) * 2002-07-25 2004-11-04 Celluar Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US7194301B2 (en) * 2003-10-06 2007-03-20 Transneuronic, Inc. Method for screening and treating patients at risk of medical disorders
PL368572A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections
PL370937A1 (pl) * 2004-10-29 2006-05-02 Sgp & Sons Ab Preparat żywieniowy i/lub farmaceutyczny do stosowania w profilaktyce i leczeniu niedoborów wchłaniania mikroelementów z przewodu pokarmowego oraz zastosowanie preparatu farmaceutycznego jako czynnika stymulującego wchłanianie mikroelementów z przewodu pokarmowego do krwi
WO2007002365A2 (en) * 2005-06-24 2007-01-04 Albert Einstein College Of Medicine Of Yeshiva University Modulation of amino acid metabolism in the hypothalamus

Also Published As

Publication number Publication date
CN101730532B (zh) 2012-05-30
US20110039935A1 (en) 2011-02-17
EA201070084A1 (ru) 2010-10-29
WO2009005464A1 (en) 2009-01-08
HK1140423A1 (en) 2010-10-15
EA018554B1 (ru) 2013-08-30
EP2173336A4 (en) 2010-11-10
AU2008271307B2 (en) 2013-10-24
JP2010532348A (ja) 2010-10-07
KR20100039874A (ko) 2010-04-16
CA2691746C (en) 2016-02-02
JP5735274B2 (ja) 2015-06-17
CN101730532A (zh) 2010-06-09
AU2008271307A1 (en) 2009-01-08
EP2173336A1 (en) 2010-04-14
CA2691746A1 (en) 2009-01-08
EP2173336B1 (en) 2016-03-30
BRPI0814184A2 (pt) 2015-03-03

Similar Documents

Publication Publication Date Title
MX2009013937A (es) Nuevo uso de compuestos quimicos farmacologicamente activos conocidos.
NZ715983A (en) Vasoprotective and cardioprotective antidiabetic therapy
WO2011031493A3 (en) Galectin-3 and cardiac resynchronization therapy
RU2014112324A (ru) Применение органического соединения для лечения синдрома нунан
JP2010532348A5 (es)
RU2008138358A (ru) Композиция с фиксированной дозой фитата и цинка
WO2010091051A3 (en) Therapeutic use of specialized endothelial progenitor cells
NZ596747A (en) Crystalline form of pemirolast
RU2011123367A (ru) Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
MX2011009506A (es) Antagonista del receptor mineralcorticoide y metodos de uso.
MY156174A (en) 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity
JP2008534621A5 (es)
WO2006104086A1 (ja) 血栓症治療剤
RU2012107483A (ru) Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек
HRP20150936T1 (hr) Pripravak koristan za sprjeäśavanje dijabetesa tip 2 i njegovih komplikacija kod predijabetiäśnih pacijenata s rezistencijom na inzulin
WO2005123096A3 (en) Compositions and methods of use of dimer digallates
JP5982715B2 (ja) 抗高血圧薬組成物
Becker-Gruenig et al. Efficacy of exercise training in congenital heart disease associated pulmonary hypertension
Minushkina Calcium antagonists in arterial hypertension treatment: specifics of lercanidipine
KR101104773B1 (ko) 신남알코올을 함유하는 고혈압 예방 및 치료용 조성물
UA105642C2 (uk) Спосіб оцінки ефективності лікування лабетололом хворих на ішемічну хворобу серця з стенокардією та артеріальною гіпертензією з порушенням діастолічної функції лівого шлуночка по "гіпертрофічному" типу
UA96878C2 (ru) Средство для лечения заболеваний сердечно-сосудистой системы и регулирования метаболических процессов
TH104398A (th) การใช้ยูเรตออกซิเดสเพื่อการรักษาหรือการป้องกันความผิดปกติหรือผลกระทบทางอ้อมที่ตามมาของหัวใจที่เกิดจากภาวะพร่องเลือดหรือผ่านเลือด
Brownlee Compartment syndrome: case report

Legal Events

Date Code Title Description
FG Grant or registration